| Nov 20 |
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
|
| Nov 14 |
We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative
|
| Nov 9 |
Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 8 |
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up
|
| Nov 8 |
Puma Biotechnology Inc (PBYI) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ...
|
| Nov 8 |
Puma Biotechnology, Inc. 2024 Q3 - Results - Earnings Call Presentation
|
| Nov 8 |
Puma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Conference Call Transcript
|
| Nov 7 |
Puma Biotech: Q3 Earnings Snapshot
|
| Nov 7 |
Puma Biotechnology Non-GAAP EPS of $0.45 beats by $0.07, revenue of $80.5M beats by $9.85M
|
| Nov 7 |
Puma Biotechnology Reports Third Quarter 2024 Financial Results
|
